Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists

Biochemical and Biophysical Research Communications

Volumn 232, Issue 2, 1997, Pages 317-322

  Yao, Yao ^a   Sei, Yoshitatsu ^a   Abbracchio, Maria P ^b   Jiang, Ji Long ^a   Kim, Yong Chul ^a   Jacobson, Kenneth A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; CELL PROTEIN; DIHYDROPYRIDINE DERIVATIVE; NAPHTHYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; 1,4 DIHYDRO 4 (2 ISOPROPYLPYRAZOLO[1,5 A]PYRIDIN 3 YL) 2,6 DIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID [2 (N BENZYL N METHYLAMINO)ETHYL] METHYL ESTER; 2 CHLORO N(6) (3 IODOBENZYL)ADENOSINE 5' N METHYLURONAMIDE; 2-CHLORO-N(6)-(3-IODOBENZYL)ADENOSINE-5'-N-METHYLURONAMIDE; 9 CHLORO 2 (2 FURYL) (1,2,4)TRIAZOLO(1,5 C)QUINAZOLIN 5 IMINE; 9-CHLORO-2-(2-FURYL)-(1,2,4)TRIAZOLO(1,5-C)QUINAZOLIN-5-IMINE; ADENOSINE RECEPTOR; DNA FRAGMENT; DRUG DERIVATIVE; N(6) (3 IODOBENZYL) 5' N METHYLCARBOXAMIDOADENOSINE; N(6)-(3-IODOBENZYL)-5'-N-METHYLCARBOXAMIDOADENOSINE; PYRAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; TRIAZOLE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL PROTECTION; CELL STRAIN HL 60; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; PATHOLOGY;

ADENOSINE; APOPTOSIS; DIHYDROPYRIDINES; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HL-60 CELLS; HUMANS; PYRAZOLES; QUINAZOLINES; RECEPTORS, PURINERGIC P1; TRIAZOLES;

EID: 0031575663     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.1997.6290     Document Type: Article

References (19)

1. Jacobson K. A., Suzuki F. Drug Devel. Res. 1997.
2. Kohno Y., Sei Y., Koshiba M., Kim H. O., Jacobson K. A. Biochem. Biophys. Res. Commun. 219:1996;904-910.
3. Kohno Y., Ji X. d., Mawhorter S. D., Koshiba M., Jacobson K. A. Blood. 88:1996;3569-3574.
4. Shneyvays V., Jacobson K. A., Shainberg A. J. Basic Clin. Physiol. Pharmacol. 1997.
5. Brambilla R., Abbracchio M. P., Ceruti S., Franceschi C., Malorni W., Giammarioli A. M., Rainaldi G., von Lubitz D. K. J. E., Jacobson K. A., Lohse M. J., Klotz K. N., Cattabeni F. Drug Devel. Res. 37:1996;181.
6. von Lubitz D., Lin R. C., Popik P., Carter M. F., Jacobson K. A. Eur. J. Pharmacol. 263:1994;59-67.
7. Abbracchio M. P., Malorni W., Ceruti S., Brambilla R., Barbieri D., Franceschi C., Giammarioli A. M., Rainaldi G., von Lubitz D. K. J. E., Jacobson K. A., Cattabeni F. J. Neurosci. 1997.
8. Strickler J., Jacobson K. A., Liang B. T. J. Clin. Invest. 98:1996;1773-1779.
9. Tracey W. R., Magee W., Masamune H., Kennedy S. P., Knight D. R., Buchholz R. A., Hill R. J. Cardiovasc. Res. 1997.
10. Karton Y., Jiang J.-l., Ji X. d., Melman N., Olah M. E., Stiles G. L., Jacobson K. A. J. Med. Chem. 39:1996;2293-2301.
11. Jiang J.-l., van Rhee A. M., Melman N., Ji X. d., Jacobson K. A. J. Med. Chem. 39:1996;4667-4675.
12. Kim Y.-C., Ji X. d., Jacobson K. A. J. Med. Chem. 39:1996;4142-4148.
13. Jacobson M., Chakravarty P. K., Johnson R. G., Norton R. Drug Devel. Res. 37:1996;131.
14. Gorczyca W., Gong J., Ardelt B., Traganos F., Darzynkiewicz Z. Cancer Res. 53:1993;3186-3192.
15. Cooke H. Trends in Biotech. 10:1992;23.
16. Towbin H., Staehelin T., Gordon J. Proc. Natl. Acad. Sci. USA. 76:1979;4350-4354.
17. Franke W. W., Heid H. W., Grund C., Winter S., Freudenstein C., Schmid E., Jarasch E., Keenan T. W. J. Cell Biol. 89:1981;485-494.
18. Farrow S. N., White J. H. M., Martinou I., Raven T., Pun K.-T., Grinham C. J., Martinou J.-C., Brown R. Nature. 374:1995;731-733.
19. Sajjadi F. G., Firestein G. S. Biochim. Biophys. Acta. 1179:1993;105-107.